Literature DB >> 34376021

Diabetes and cardiovascular diseases are associated with the worsening of intermittent hypoxaemia.

Tuomas Karhu1,2, Sami Myllymaa1,2, Sami Nikkonen1,2, Diego R Mazzotti3, Antti Kulkas1,4, Juha Töyräs1,5,6, Timo Leppänen1,2,6.   

Abstract

Intermittent hypoxaemia is a risk factor for numerous diseases. However, the reverse pathway remains unclear. Therefore, we investigated whether pre-existing hypertension, diabetes or cardiovascular diseases are associated with the worsening of intermittent hypoxaemia. Among the included 2,535 Sleep Heart Health Study participants, hypertension (n = 1,164), diabetes (n = 170) and cardiovascular diseases (n = 265) were frequently present at baseline. All participants had undergone two polysomnographic recordings approximately 5.2 years apart. Covariate-adjusted linear regression analyses were utilized to investigate the difference in the severity of intermittent hypoxaemia at baseline between each comorbidity group and the group of participants free from all comorbidities (n = 1,264). Similarly, we investigated whether the pre-existing comorbidities are associated with the progression of intermittent hypoxaemia. Significantly higher oxygen desaturation index (β = 1.77 [95% confidence interval: 0.41-3.13], p = 0.011), desaturation severity (β = 0.07 [95% confidence interval: 0.00-0.14], p = 0.048) and desaturation duration (β = 1.50 [95% confidence interval: 0.31-2.69], p = 0.013) were observed in participants with pre-existing cardiovascular diseases at baseline. Furthermore, the increase in oxygen desaturation index (β = 3.59 [95% confidence interval: 1.78-5.39], p < 0.001), desaturation severity (β = 0.08 [95% confidence interval: 0.02-0.14], p = 0.015) and desaturation duration (β = 2.60 [95% confidence interval: 1.22-3.98], p < 0.001) during the follow-up were higher among participants with diabetes. Similarly, the increase in oxygen desaturation index (β = 2.73 [95% confidence interval: 1.15-4.32], p = 0.001) and desaturation duration (β = 1.85 [95% confidence interval: 0.62-3.08], p = 0.003) were higher among participants with cardiovascular diseases. These results suggest that patients with pre-existing diabetes or cardiovascular diseases are at increased risk for an expedited worsening of intermittent hypoxaemia. As intermittent hypoxaemia is an essential feature of sleep apnea, these patients could benefit from the screening and follow-up monitoring of sleep apnea.
© 2021 The Authors. Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.

Entities:  

Keywords:  cardiovascular disease; desaturation; diabetes; hypoxaemia; progression; sleep apnea

Mesh:

Substances:

Year:  2021        PMID: 34376021      PMCID: PMC8766861          DOI: 10.1111/jsr.13441

Source DB:  PubMed          Journal:  J Sleep Res        ISSN: 0962-1105            Impact factor:   3.981


  39 in total

1.  Increased incidence of cardiovascular disease in middle-aged men with obstructive sleep apnea: a 7-year follow-up.

Authors:  Yüksel Peker; Jan Hedner; Jeanette Norum; Holger Kraiczi; Jan Carlson
Journal:  Am J Respir Crit Care Med       Date:  2002-07-15       Impact factor: 21.405

Review 2.  Sleep Apnea and Cardiovascular Disease: An Enigmatic Risk Factor.

Authors:  John S Floras
Journal:  Circ Res       Date:  2018-06-08       Impact factor: 17.367

Review 3.  Estimation of the global prevalence and burden of obstructive sleep apnoea: a literature-based analysis.

Authors:  Adam V Benjafield; Najib T Ayas; Peter R Eastwood; Raphael Heinzer; Mary S M Ip; Mary J Morrell; Carlos M Nunez; Sanjay R Patel; Thomas Penzel; Jean-Louis Pépin; Paul E Peppard; Sanjeev Sinha; Sergio Tufik; Kate Valentine; Atul Malhotra
Journal:  Lancet Respir Med       Date:  2019-07-09       Impact factor: 30.700

4.  Prospective study of the association between sleep-disordered breathing and hypertension.

Authors:  P E Peppard; T Young; M Palta; J Skatrud
Journal:  N Engl J Med       Date:  2000-05-11       Impact factor: 91.245

5.  Obstructive sleep apnea and systemic hypertension: longitudinal study in the general population: the Vitoria Sleep Cohort.

Authors:  Irene Cano-Pumarega; Joaquín Durán-Cantolla; Felipe Aizpuru; Erika Miranda-Serrano; Ramón Rubio; Cristina Martínez-Null; Javier de Miguel; Carlos Egea; Laura Cancelo; Ainhoa Alvarez; Marta Fernández-Bolaños; Ferrán Barbé
Journal:  Am J Respir Crit Care Med       Date:  2011-08-25       Impact factor: 21.405

6.  Nocturnal intermittent hypoxia predicts prevalent hypertension in the European Sleep Apnoea Database cohort study.

Authors:  Ruzena Tkacova; Walter T McNicholas; Martin Javorsky; Ingo Fietze; Pawel Sliwinski; Gianfranco Parati; Ludger Grote; Jan Hedner
Journal:  Eur Respir J       Date:  2014-08-07       Impact factor: 16.671

Review 7.  Epidemiology, risk factors, and consequences of obstructive sleep apnea and short sleep duration.

Authors:  Nabil M Al Lawati; Sanjay R Patel; Najib T Ayas
Journal:  Prog Cardiovasc Dis       Date:  2009 Jan-Feb       Impact factor: 8.194

Review 8.  Obstructive sleep apnea and hypertension: an update.

Authors:  Tomas Konecny; Tomas Kara; Virend K Somers
Journal:  Hypertension       Date:  2013-12-30       Impact factor: 10.190

9.  Feasibility of Single Channel Oximetry for Mass Screening of Obstructive Sleep Apnea.

Authors:  Joachim A Behar; Niclas Palmius; Qiao Li; Silverio Garbuio; Fabìola P G Rizzatti; Lia Bittencourt; Sergio Tufik; Gari D Clifford
Journal:  EClinicalMedicine       Date:  2019-06-07

10.  The National Sleep Research Resource: towards a sleep data commons.

Authors:  Guo-Qiang Zhang; Licong Cui; Remo Mueller; Shiqiang Tao; Matthew Kim; Michael Rueschman; Sara Mariani; Daniel Mobley; Susan Redline
Journal:  J Am Med Inform Assoc       Date:  2018-10-01       Impact factor: 4.497

View more
  1 in total

Review 1.  Association and Risk Factors for Obstructive Sleep Apnea and Cardiovascular Diseases: A Systematic Review.

Authors:  Amal K Mitra; Azad R Bhuiyan; Elizabeth A Jones
Journal:  Diseases       Date:  2021-12-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.